PSYK — Psyk ETF

PSYK Fund Overview

PSYK — Psyk ETF is a US ETF managed by ETF Series Solutions, categorised as China Blend / Core Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.

• Type: US ETF
• Manager: ETF Series Solutions
• Category: China Blend / Core Equity
• Assets under management: $1.91M
• 1-year return: -15.7%
• Ticker: PSYK
• SEC CIK: 0001540305
• SEC series ID: S000072630
• Share class ID: C000229024

PSYK Investment Objective and Strategy

Psyk ETF describes its objective and strategy as follows, from its latest prospectus filed with the SEC by ETF Series Solutions.

Investment objective

The PSYK ETF (the Fund) seeks to track the performance, before fees and expenses, of the Enhanced Consciousness Index (the Index).

Principal investment strategy

The Fund uses a passive management (or indexing) approach to track the performance, before fees and expenses, of the Index. Enhanced Consciousness Index The Index is a rules-based index that tracks the performance of a portfolio of companies that have business activity in the fields of psychedelic treatment used to address medical conditions in legal pharmacological applications under the applicable countrys laws. Psychedelic drugs are a group of substances that may be able to be used to change and enhance sensory perceptions, thought processes, and energy levels. If fewer than 25 psychedelic treatment companies qualify for inclusion in the Index, the Index will also include neurology biopharmaceuticals companies. Neurology biopharmaceuticals refer to any pharmaceutical drug product manufactured in, extracted from, or semi-synthesized from biological sources for the treatment of disorders and diseases involving the central and peripheral nervous systems.

Neurology biopharmaceuticals companies may also include companies involved in the development of gene-based medicines for neurological diseases. The Index uses a natural language processing algorithm to review publicly available data to identify companies that have business activity in the fields of psychedelic treatment (or neurology biopharmaceuticals, if applicable). Construction of the Index begins with the universe of equity securities and depositary receipts (including depositary receipts of companies in developed or emerging markets) that have a market capitalization of at least $50 million ($40 million for companies already included in the Index) and meet certain liquidity thresholds (collectively, the Index Universe). Companies that have their primary listing in Australia, China, or Saudi Arabia are not eligible for inclusion.

Companies are selected for inclusion in the Index by Solactive AG (Solactive), using ARTIS , Solactives proprietary natural language processing algorithm. ARTIS uses key words to review large volumes of publicly available data, such as company annual reports, published business descriptions, company publications, and financial news reports, which Solactive believes will identify and classify companies as having business activity in the fields of psychedelic treatment or neurology biopharmaceuticals and then ranks the companies based on the number and quality of key word hits in the companys data. The ARTIS classification system considers the frequency, relevance, and context of key words found in the companys data. The ARTIS classification system is different than traditional classification systems because it utilizes natural language processing, such as key word searching, whereas traditional classifications systems may utilize backward looking metrics, such as a companys past profits or revenue, to determine the classification of a company.

Solactive then reviews the rankings provided by ARTIS for relevance and removes companies that were incorrectly identified as psychedelic treatment companies (or neurology biopharmaceuticals, if applicable). At the time of each reconstitution of the Index, the top ranked 25 psychedelic treatment companies are added successively by their ranking and weighted based on their market capitalization. If there are fewer than 25 psychedelic treatment companies included in the Index after this process, neurology biopharmaceuticals companies are added successively and weighted based on their market capitalization until there is a minimum of 25 Index components. Index constituents are weighted based on their market capitalization, subject to a minimum weighting of 0.2% for all Index components and a maximum weighting of 7% for psychedelic treatment companies and 4% for neurology biopharmaceuticals companies.

For companies that have a market capitalization greater than $100 billion, the maximum weighting of that company is 2.5%. Additionally, the aggregate weight of companies with an individual weight greater than 5% is capped at 45%, and any remaining companies are capped at 4.5%. The Index tracks companies that are involved in the development of regulated and controlled pharmaceuticals and therapies, under the applicable countrys laws, in the psychedelics and neurology biopharmaceuticals industries that could potentially be used to confront specific illnesses that are not being fully addressed with currently available treatments. To date, no psychedelic drug product other than ketamine has received marketing approval on the basis of safety and efficacy from the U.S. Food and Drug Administration (FDA) or Health Canada (Canadas governmental agency responsible for national health policy) and, accordingly, no other psychedelic drug may be commercially marketed or sold.

Companies with business operations in these fields include companies that develop pharmaceuticals and therapies using psychedelics or neurology biopharmaceuticals for the potential treatment of medical conditions. Psychedelics, sometimes referred to as hallucinogens, are substances that alter perception, mood, and cognitive processes. Ketamine is a dissociative drug that is sometimes labeled a psychedelic and may produce psychedelic effects. Ketamine-based products have been approved by the FDA for certain therapeutics. The Index is reconstituted annually on the first Wednesday in March based on information as of ten business days before the scheduled reconstitution date. The Index is rebalanced quarterly on the first Wednesday in each March, June, September, and December. As of November 15, 2021, the Index was composed of 25 constituents, 18 of which were classified by Solactive as psychedelic treatment companies and seven of which were classified by Solactive as neurology biopharmaceuticals companies.

The Index was developed in 2021 and is owned by Elemental Advisors LLC (the Index Provider). The Index is administered and calculated by Solactive, the Index calculation agent. The Index Provider is independent of Solactive, the Fund, and the Funds investment adviser. The Funds Investment Strategy The Fund will not invest directly in or hold ownership in any companies that engage in psychedelics-related business unless permitted by national and local laws of the relevant jurisdiction, including U.S. federal and state laws. Accordingly, the Fund does not currently invest (directly or indirectly) in companies located in the United States if their psychedelics-related business activities are illegal under U.S. federal law, even if such activities are legal under state law. In addition, the Fund will not invest directly in or hold ownership of any companies that engage in cannabis-related business.

The Fund will generally use a replication strategy to achieve its investment objective, meaning the Fund will generally invest in all of the component securities of the Index in the same approximate proportions as in the Index. However, the Fund may use a representative sampling strategy, meaning it may invest in a sample of the securities in the Index whose risk, return, and other characteristics closely resemble the risk, return, and other characteristics of the Index as a whole, when the Funds adviser believes it is in the best interests of the Fund ( e.g. , when replicating the Index involves practical difficulties or substantial costs, an Index constituent becomes temporarily illiquid, unavailable, or less liquid, or as a result of legal restrictions or limitations that apply to the Fund but not to the Index).

To the extent the Index concentrates ( i.e. , holds more than 25% of its total assets) in the securities of a particular industry or group of related industries, the Fund will concentrate its investments to approximately the same extent as the Index. The Fund expects to invest a significant portion of its assets in small- and mid-cap companies. The Fund is considered to be non-diversified, which means that it may invest more of its assets in the securities of a single issuer or a smaller number of issuers than if it were a diversified fund.

PSYK Performance

Total returns for PSYK (as of 2026-10-01), from SEC filings.

PSYK Risk Information

Risk metrics for PSYK, derived from monthly returns in SEC filings.

• 1-year volatility (annualised): 23.9%

PSYK Costs and Fees

PSYK costs about $75 per $10,000 invested per year in fund expenses.

• Net expense ratio: 0.75%
• Gross expense ratio: 0.90%
• Brokerage commissions: 8.85 bps of average net assets (SEC N-CEN)

PSYK Cashflows

Over the 12 months to 2023-02, Psyk ETF had net inflows of $2.08M, from monthly SEC N-PORT filings.

PSYK Debt Constituents

No individual debt constituents are reported in Psyk ETF's latest SEC N-PORT filing.

PSYK Prospectus and SEC Filings

Official Psyk ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.

• Prospectus (485BPOS) — filed 2021-07-23
• Prospectus amendment (485APOS) — filed 2022-01-21
• Portfolio holdings (N-PORT) — filed 2023-04-27
• Portfolio holdings (N-PORT) — filed 2023-01-27
• Portfolio holdings (N-PORT) — filed 2022-10-28
• Annual census (N-CEN) — filed 2023-02-13

Related Funds

Other China Blend / Core Equity funds tracked on ABC INVEST:

• Fiera Capital Emerging Markets Fund (RIMIX)
• 2ndVote Society Defended ETF (EGIS)
• Infusive® Compounding Global Equities ETF (JOYY)
• Clough China Fund (CHNAX)
• Franklin FTSE Hong Kong ETF (FLHK)

Data Sources

ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.